

Contract Manufacturing

130 forms and doses | 25 million packages a year | Key therapeutic areas |
Highly potent products up to OEB 5 | EU GMP compliant





TZF POLFA – 200 YEARS OF EXPERIENCE IN THE PHARMACEUTICAL INDUSTRY

200 years of tradition have allowed TZF Polfa to develop a comprehensive pharmaceutical portfolio that continuously evolves to meet patients' changing needs. Building on this legacy, we have established the most advanced high-potency drug manufacturing facility in Central and Eastern Europe. The Center for the Development and Manufacturing of Highly Potent Drugs features two dedicated sterile production lines – including one capable of handling high-potency compounds up to OEB 5 – ensuring maximum safety and product integrity.

Our facility is equipped to produce an extensive variety of forms and dosages, manufacturing over 25 million packages annually across a wide range of strengths and formats. We offer a comprehensive portfolio of pharmaceutical dosage forms.



OUR SPECIALIZATION



Tablets and capsules



**Lyophilizates for
injectable solutions**



Powders for suspension



**Injectable solutions
and suspensions**




**Gels and pharmaceutical
aerosols**





We focus on delivering high-quality generics, ensuring accessible and effective therapies for patients worldwide. Our production encompasses several therapeutical groups, including:



Anti-infectives



Dermatology



Diabetology



Oncology & Rheumatology



Central Nervous System (CNS)



Alimentary Tract & Metabolism



TZF Polfa offers flexible cooperation models tailored to our partners' needs, including:

1

CDMO

2

CMO

3

License In & License Out

4

Distribution agreements



INJECTABLES – DRY POWDERS

Pharmaceutical forms:

- powders for suspension, solution for injection, infusion
- lyophilized powders for suspension, solution for injection, infusion

Secondary packaging:

- folding boxes for individual vials

New production facilities:

- availability: IIIQ2028 (lyophilisation)

Primary packaging:

- glass vials (dry powder filling) 20R, 50R, 100R and 200R, flip-off cap
- glass vials (dry powder filling, lyophilisation) 2R, 6R, 10R, 20R, 30R, 50R, flip-off cap

Estimated annual capacities:

- 2M (lyophilisation) – 15M (filling) vials



INJECTABLES – STERILE SOLUTIONS

Pharmaceutical forms:

- solutions in glass ampules
- solutions or suspensions in glass cartridges
- solutions in glass vials

Secondary packaging:

- folding boxes for individual vials and for 5 or 10 for ampules and cartridges

Primary packaging:

- ampules 2 ml and 5 ml
- cartridges 3 ml
- vials 2R, 6R, 10R, 20R, 30R, 50R

Estimated annual capacities:

- 10M (ampules); 6M (cartridges)
10M (vials)



INJECTABLES – HIGH-POTENT

(up to OEB 5)

Pharmaceutical forms:

- solutions in glass vials
- solutions in prefilled syringes
- lyophilized powder for injection in vials

Primary packaging:

- PFS 0.5 ml, 1 ml, 5 ml
- vials 2R, 8R, 10R, 30R, 50R

Secondary packaging:

- folding boxes for individual vials/PFS

New production facilities:

- availability: IVQ2027

Estimated annual capacities:

- between 0.6M (lyophilisation)
– 3M (filling) vials or PFS



SOLID ORAL DOSAGE FORMS

Pharmaceutical forms:

- tablets & film coated tablets (sugar, organic solvent); size 5 mm–19 mm
- hard gelatine capsules; size 4–00
- dry powders, granulates for oral suspensions; dose 3–30 g

Primary packaging:

- blistering Alu-Alu, Alu-PVC, PVdC
- containers and jars (for tablets and capsules)
- bottles (glass, plastic) in different sizes 30–200 ml (for powders and granulates)

Secondary packaging:

- folding boxes in different sizes and configurations

Estimated annual capacities:

- 100M (tablets or capsules)
dry powders 0.5M bottles



SEMISOLID DOSAGE FORMS

Pharmaceutical forms:

- gels
- ointments
- pressurized aerosols

Secondary packaging:

- folding boxes for individual tubes and monoblocks

Primary packaging:

- aluminium tubes 5–50 g
- PE tubes 5–15 g
- aluminium monoblocks 35 mm (50–110 ml)

Estimated annual capacities:

- 1M (gels or ointments)
- 2M aerosol cans

**Active Pharmaceutical
Ingredients and Intermediates**

**Estimated annual capacities:
approx. 15 batches**

Technological platforms

- synthesis at $-10 \div 110^{\circ}\text{C}$
- crystallization at $-10 \div 80^{\circ}\text{C}$
- vacuum and pressure filtration
- ultrafiltration
- vacuum distillation & drying
- grinding
- batch size 100–1000 l

Other services

- chemical & microbiological analysis
- release by qualified person
- procurement of starting materials
- filling of bottles with nonsterile solutions
- API micronization
- serialization EU, other countries possible





CONTACT US!

Let's discuss how our contract manufacturing services can accelerate your pharmaceutical projects. Get in touch today!

cmo@tzf.pl

TZ Polfa

Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.
A. Fleminga 2 Street, 03-176 Warsaw, Poland
NIP 5250000564 | REGON 010721743 | KRS 27471

www.tzf.pl

TZF236/26/09/2025



Scan the QR code
to learn more about
our services

